Does Thyroid dysfunction correlates with iron overload in Eβ thalassemia patients? A study from a tertiary care thalassemia center in India

Background and Aim: Large number of Haemoglobin E-beta thalassaemia (Hb E/β-thalassaemia) patients show iron overloads and related end-organ damage irrespective of transfusion requirements. The prevalence of hypothyroidism in Indian population is approximately 11%. We studied the relationship between thyroid dysfunction and iron overload in Hb E/β-thalassaemia. Materials and Methods: The study included Eβ-thalassemia patients above the age of 10 years. Patient's serum ferritin level evaluated for the evaluation of iron status and thyroid-stimulating hormone, FT4, T3 for thyroid function status. Results: The study was conducted from January 2016 to December 2017. Of 50 Eβ-thalassemia patients, there were 22 females; the mean age was 19 years (range: 12–47 years). A total of 22 (44%) patients showed thyroid dysfunction; overt hypothyroidism seen in 6 (12%) patients with mean ferritin level of 1077 ng/ml and subclinical hypothyroidism seen in 16 (32%) patients with mean ferritin level of 1200 ng/ml. Normal thyroid function seen in 28 (56%) of patients with mean ferritin level of 1155 ng/ml. Conclusion: The prevalence of thyroid dysfunction was found to be higher in Hb E/β-thalassaemia patients, but a definite correlation with the serum ferritin level could not be established.

[1]  A. Hagag,et al.  Study of gonadal hormones in Egyptian female children with sickle cell anemia in correlation with iron overload: Single center study. , 2016, Hematology/oncology and stem cell therapy.

[2]  A. Inati,et al.  Endocrine and Bone Complications in β-Thalassemia Intermedia: Current Understanding and Treatment , 2015, BioMed research international.

[3]  P. Mandal,et al.  Does Profile of Hemoglobin Eβ-thalassemia Patients Change After Splenectomy? Experience of a Tertiary Thalassemia Care Centre in Eastern India , 2015, Indian Journal of Hematology and Blood Transfusion.

[4]  S. Maji,et al.  Present scenario of hemoglobinopathies in West Bengal, India: An analysis of a large population , 2014 .

[5]  M. Cappellini,et al.  Beta-Thalassaemia Intermedia: Evaluation of Endocrine and Bone Complications , 2014, BioMed research international.

[6]  M. Karimi,et al.  Hypothyroidism in β-Thalassemia Intermedia Patients with and without Hydroxyurea , 2014, Iranian journal of medical sciences.

[7]  S. Kalra,et al.  Prevalence of hypothyroidism in adults: An epidemiological study in eight cities of India , 2013, Indian journal of endocrinology and metabolism.

[8]  A. Phatarpekar,et al.  Endocrine abnormalities in children with Beta thalassaemia major , 2013 .

[9]  E. Vichinsky,et al.  ENDOCRINE AND BONE DISEASE , 2013 .

[10]  M. Angastiniotis,et al.  Growth and endocrine disorders in thalassemia: The international network on endocrine complications in thalassemia (I-CET) position statement and guidelines , 2013, Indian journal of endocrinology and metabolism.

[11]  Vip Viprakasit,et al.  Deferasirox reduces iron overload significantly in nontransfusion-dependent thalassemia: 1-year results from a prospective, randomized, double-blind, placebo-controlled study. , 2012, Blood.

[12]  S. Perrotta,et al.  Iron chelation with deferasirox in adult and pediatric patients with thalassemia major: efficacy and safety during 5 years' follow-up. , 2011, Blood.

[13]  B. Leikind,et al.  An Assessment of , 2011 .

[14]  M. Gladwin,et al.  Sickle-cell disease , 2010, The Lancet.

[15]  M. Cappellini,et al.  Age‐related complications in treatment‐naïve patients with thalassaemia intermedia , 2010, British journal of haematology.

[16]  N. Ahmed,et al.  Frequency of hypothyroidism in patients of beta-thalassaemia. , 2010, JPMA. The Journal of the Pakistan Medical Association.

[17]  M. Cappellini,et al.  Thalassaemia Intermedia: an Update , 2009, Mediterranean journal of hematology and infectious diseases.

[18]  I. Maisnam,et al.  A study on endocrine dysfunction in thalassaemia. , 2008, Journal of the Indian Medical Association.

[19]  W. Mula-Abed,et al.  Prevalence of endocrinopathies in patients with Beta-thalassaemia major - a cross-sectional study in oman. , 2008, Oman medical journal.

[20]  D. Reboussin,et al.  Thyroid-stimulating hormone and free thyroxine levels in persons with HFE C282Y homozygosity, a common hemochromatosis genotype: the HEIRS study. , 2008, Thyroid : official journal of the American Thyroid Association.

[21]  A. Chuansumrit,et al.  A scoring system for the classification of β‐thalassemia/Hb E disease severity , 2008, American journal of hematology.

[22]  G. Umpierrez,et al.  Therapy Insight: metabolic and endocrine disorders in sickle cell disease , 2008, Nature Clinical Practice Endocrinology &Metabolism.

[23]  T. Ganz,et al.  Liver iron concentrations and urinary hepcidin in beta-thalassemia. , 2007, Haematologica.

[24]  H. Karamifar,et al.  Endocrine Function in Thalassemia Intermedia , 2006, International journal of biomedical science : IJBS.

[25]  C. Acampora,et al.  Longitudinal Study on Thyroid Function in Patients with Thalassemia Major , 2006, Journal of pediatric endocrinology & metabolism : JPEM.

[26]  A. Zervas,et al.  Assessment of thyroid function in two hundred patients with beta-thalassemia major. , 2002, Thyroid : official journal of the American Thyroid Association.

[27]  V. Wright,et al.  Endocrine disease. , 1993, Current opinion in rheumatology.

[28]  B. Bagni,et al.  Primary hypothyroidism and the low T3 syndrome in thalassaemia major , 1983, Archives of disease in childhood.

[29]  N. Matsaniotis,et al.  Serum ferritin in beta-thalassaemia intermedia. , 1980, Lancet.